These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28808428)

  • 41. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
    Nagasaka M; Zaki M; Issa M; Kim H; Abrams J; Sukari A
    Laryngoscope; 2017 Oct; 127(10):2260-2264. PubMed ID: 28271529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
    Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
    Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
    Rades D; Strojan P; Seidl D; Janssen S; Bajrovic A; Kazic N; Hakim SG; Wollenberg B; Schild SE
    J Craniomaxillofac Surg; 2016 Sep; 44(9):1436-40. PubMed ID: 27499514
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.
    Araki D; Redman MW; Martins R; Eaton K; Baik C; Chow L; Goulart B; Lee S; Santana-Davila R; Liao J; Parvathaneni U; Laramore G; Futran N; Mendez E; Bhrany A; Rodriguez CP
    Head Neck; 2016 Sep; 38(9):1318-23. PubMed ID: 27061333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
    Tao Y; Aupérin A; Graff P; Lapeyre M; Grégoire V; Maingon P; Geoffrois L; Verrelle P; Calais G; Gery B; Martin L; Alfonsi M; Deprez P; Bardet E; Pignon T; Rives M; Sire C; Bourhis J
    Oral Oncol; 2017 Aug; 71():61-66. PubMed ID: 28688693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
    Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
    Zandberg DP; Cullen K; Bentzen SM; Goloubeva OG
    Oral Oncol; 2018 Nov; 86():132-140. PubMed ID: 30409293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.
    Adkins D; Ley J; Oppelt P; Wildes TM; Gay HA; Daly M; Rich J; Paniello RC; Jackson R; Pipkorn P; Nussenbaum B; Trinkaus K; Thorstad W
    Oral Oncol; 2017 Sep; 72():26-31. PubMed ID: 28797458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).
    Walsh L; Gillham C; Dunne M; Fraser I; Hollywood D; Armstrong J; Thirion P
    Radiother Oncol; 2011 Jan; 98(1):38-41. PubMed ID: 21159400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy in locally advanced head and neck squamous cell carcinoma.
    Gyawali B; Shimokata T; Honda K; Ando Y
    Cancer Treat Rev; 2016 Mar; 44():10-6. PubMed ID: 26924194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.
    Melotek JM; Cooper BT; Koshy M; Silverman JS; Spiotto MT
    J Otolaryngol Head Neck Surg; 2016 Nov; 45(1):62. PubMed ID: 27881143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complication and surgical site infection for salvage surgery in head and neck cancer after chemoradiotherapy and bioradiotherapy.
    Suzuki H; Hanai N; Nishikawa D; Fukuda Y; Hasegawa Y
    Auris Nasus Larynx; 2017 Oct; 44(5):596-601. PubMed ID: 28043710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of high-dose Cisplatin-based chemoradiotherapy and Cetuximab-based bioradiotherapy for p16-positive oropharyngeal squamous cell carcinoma in the context of revised HPV-based staging.
    Onita B; Lester D R T; Iman A A; Jergin C; Shawn I
    Rep Pract Oncol Radiother; 2018; 23(5):451-457. PubMed ID: 30210266
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
    Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
    Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study.
    Jeong ISD; Mo H; Nguyen A; Chong EG; Tsai HHC; Moyers J; Kim M; Lacy C; Shah V; Lau E; Xu Y; Cao H
    Exp Hematol Oncol; 2020; 9():19. PubMed ID: 32775042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck.
    Awan MJ; Nedzi L; Wang D; Tumati V; Sumer B; Xie XJ; Smith I; Truelson J; Hughes R; Myers LL; Lavertu P; Wong S; Yao M
    Ann Oncol; 2018 Apr; 29(4):998-1003. PubMed ID: 29346519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer.
    Noronha V; Patil VM; Joshi A; Mahimkar M; Patel U; Pandey MK; Chandrasekharan A; Dsouza H; Bhattacharjee A; Mahajan A; Sabale N; Agarwal JP; Ghosh-Laskar S; Budrukkar A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Nair S; Thiagarajan S; Banavali S; Prabhash K
    Oncotarget; 2020 Jan; 11(4):399-408. PubMed ID: 32064043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concurrent Radiotherapy With Cetuximab or Platinum-based Chemotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Lu SM; Lien WW
    Am J Clin Oncol; 2018 Jan; 41(1):95-99. PubMed ID: 26353121
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A
    Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.